Craft

Advanced
  • Home
  •  / Infant Bacterial Therapeutics
Infant Bacterial Therapeutics

Infant Bacterial Therapeutics

Infant Bacterial Therapeutics Summary

Company Summary

Overview
Infant Bacterial Therapeutics (IBT) is a clinical-stage pharmaceutical company offering drugs influencing the infant microbiome. It develops drug candidate IBP-9414 to prevent necrotizing enterocolitis in premature infants.
Type
Public
Status
Active
Founded
2013
HQ
Stockholm, SE | view all locations
Website
http://ibtherapeutics.com/
Cybersecurity rating
Sectors

Table of Contents

Key People

  • Peter Rothschild

    Peter Rothschild, Chairman of the Board

    • Staffan Strömberg

      Staffan Strömberg, CEO

      • Margareta Hagman

        Margareta Hagman, Director

        • Anthon Jahreskog

          Anthon Jahreskog, Director

          LocationsView all

          1 location detected

          • Stockholm, Stockholms län HQ

            Sweden

            Bryggargatan 10

          Infant Bacterial Therapeutics Financials

          Summary Financials

          Net income (Q1, 2026)
          (kr22.9M)
          Cash (Q1, 2026)
          kr131.9M
          EBIT (Q1, 2026)
          (kr23.5M)

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX